PubMed:32842509
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 31-39 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T2 | 100-108 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T3 | 309-317 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T4 | 353-361 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T5 | 568-576 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T6 | 839-847 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 70-71 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T2 | 180-181 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T3 | 916-923 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 223-228 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T2 | 331-335 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T3 | 431-435 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T4 | 584-603 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T6 | 593-603 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T7 | 664-673 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
| T8 | 791-795 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T9 | 820-825 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T10 | 855-874 | Chemical | denotes | protease inhibitors | http://purl.obolibrary.org/obo/CHEBI_37670|http://purl.obolibrary.org/obo/CHEBI_60258 |
| T12 | 864-874 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 395-412 | http://purl.obolibrary.org/obo/GO_0019079 | denotes | viral replication |
| T2 | 395-412 | http://purl.obolibrary.org/obo/GO_0019058 | denotes | viral replication |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1 | 31-41 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 7 | 100-110 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 8 | 309-317 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 9 | 353-363 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 10 | 568-578 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 11 | 839-849 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-95 | Sentence | denotes | Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method. |
| T2 | 96-250 | Sentence | denotes | The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. |
| T3 | 251-348 | Sentence | denotes | An alternative powerful additional approach to counteract COVID-19 is in silico drug repurposing. |
| T4 | 349-443 | Sentence | denotes | The SARS-CoV-2 main protease is essential for viral replication and an attractive drug target. |
| T5 | 444-604 | Sentence | denotes | In this study, we used the virtual screening protocol with both long-range and short-range interactions to select candidate SARS-CoV-2 main protease inhibitors. |
| T6 | 605-761 | Sentence | denotes | First, the Informational spectrum method applied for small molecules was used for searching the Drugbank database and further followed by molecular docking. |
| T7 | 762-924 | Sentence | denotes | After in silico screening of drug space, we identified 57 drugs as potential SARS-CoV-2 main protease inhibitors that we propose for further experimental testing. |